Written by Daniel Carter,
Healthcare keeps moving. New treatments arrive. Clinical guidance changes. Familiar therapies gain new uses. Peptides are part of this shift. Nearly 100 peptide medicines have now received approval worldwide. Insulin remains the best-known example. However, peptide therapy now reaches far beyond diabetes. Some medicines support cancer care. Others help manage pain. Peptides also play roles in bone health. They can support rare disease treatment and diagnostic imaging.
Why should healthcare professionals pay attention? Simple. Peptide research may affect prescribing and monitoring. It may also shape administration and patient education. Advanced chemistry training is not required. Still, professionals need a clear understanding of the evidence. In a changing field, continuing education matters. It helps clinicians recognize new benefits, risks, and limitations.
How are peptide medicines used across healthcare?
Peptides are short chains of amino acids. Proteins also contain amino acids. However, proteins are usually larger. They are also more complex.
Many natural peptides act as hormones. Others work as chemical messengers. Therapeutic peptides can copy these natural actions. Some block them. Others change a biological pathway’s response.
By 2022, more than 80 peptide medicines had entered global markets. Another 170 remained in clinical development. Global sales had passed $70 billion by 2019 (Wang et al., 2022).
Their clinical uses vary widely. Examples include:
- Exenatide for type 2 diabetes care
- Teriparatide for osteoporosis
- Teduglutide for short bowel syndrome
- Ziconotide for severe chronic pain
Other medicines serve different specialties. Enfuvirtide blocks HIV-1 entry into cells. Lutetium-177 dotatate targets certain neuroendocrine tumors.
These examples show an important point. Peptide treatment is not limited to one specialty. It can affect medication reviews in many clinical settings.
Healthcare professionals may encounter these medicines during routine care. A nurse may manage administration. A pharmacist may review interactions or storage. A case manager may coordinate follow-up care. Basic peptide knowledge can therefore improve team communication.
How is better design changing peptide drug development?
Peptide research once relied on slower laboratory methods. Modern design has changed that process. Solid-phase peptide synthesis is one major advance. It lets researchers build amino acid chains in sequence. The process is carefully controlled. Robert Bruce Merrifield developed the method while researching peptides. His work later earned the 1984 Nobel Prize in Chemistry.
Automation has improved the process further. Modern systems can increase speed. They can also improve accuracy and consistency. Researchers can now screen large peptide libraries. Each library may contain many possible candidates.
Small structural changes can also make a difference. One amino acid change may improve stability. It may also strengthen biological activity. Healthcare professionals can better assess treatment effects by understanding them at a practical level. Cyclization can make a peptide more rigid. Fatty-acid attachment may extend its activity. Liraglutide provides a clear example. It contains a C16 fatty-acid chain. A glutamic acid spacer connects the chain to the peptide. The result is longer activity (Wang et al., 2022).
These modifications affect more than laboratory performance. They may change dosing intervals. They can influence storage needs and treatment adherence. They may also affect how adverse reactions develop. Promising? Yes. Even so, every candidate needs careful clinical testing. Successful molecular design does not guarantee a useful medicine.
How is artificial intelligence changing peptide discovery?
Artificial intelligence can review huge amounts of peptide data. It can compare sequences and structures. It can also assess electrical charges. Possible target interactions can be studied too.
What can that achieve? Faster screening.
Some systems estimate binding strength. Others predict:
- Toxicity
- Solubility
- Stability
Certain models can also create new peptide sequences. These sequences follow selected research goals. This process may help teams reject weaker candidates sooner. It may also reduce early development costs.
However, AI predictions are not clinical proof. Every model depends on its training data. Incomplete data can produce weak results. Biased datasets may create misleading patterns. An algorithm may identify a promising structure. However, it cannot prove that the structure will help patients.
Laboratory testing remains essential. Animal studies may follow. Human trials must then confirm:
- Dosing
- Safety
- Effectiveness
AI can support discovery. It cannot replace evidence. Similar concerns shape the use of AI diagnostic tools across healthcare.
Healthcare professionals should keep this difference clear. Early research can sound impressive. However, it may still be far from clinical use.
Careful interpretation becomes especially important in public media. Patients may confuse computational promise with an available treatment.
Why is peptide delivery still so difficult?
Peptides often break down quickly inside the body. Digestive enzymes may damage them before absorption. Their size can also restrict movement across cell membranes. Electrical charge may create another barrier.
As a result, many peptide medicines still rely on injections (Xiao et al., 2025).
Researchers are studying other routes. Options include:
- Nasal systems
- Transdermal systems
- Oral formulations
- Extended-release formulations
Can oral peptide treatment work? Sometimes. Even then, absorption may remain low or inconsistent.
A formulation must protect the peptide during digestion. It must also support movement through the intestinal wall.
These challenges explain an important problem. A promising peptide may still lack a practical delivery method.
Delivery affects several areas of care:
- Comfort
- Storage
- Adherence
- Dosing frequency
- Staff training
A new formulation may change the entire patient conversation. For example, extended release may reduce dosing frequency. However, it may create new storage needs. It may also require different monitoring.
Healthcare teams need to understand these tradeoffs. Only then can they advise patients clearly.
What are the main benefits and limits of peptide medicines?
Peptides attract attention because they can bind targets precisely. Their structures can also cover larger protein surfaces. Many small-molecule drugs cover smaller areas. That difference may matter clinically. Protein interactions may involve areas between 1,500 and 3,000 square angstroms. Small molecules often cover only 300 to 1,000 square angstroms (Wang et al., 2022).
This larger contact area may help peptides influence difficult protein interactions. Still, precision does not remove every limitation. Some peptides break down quickly. Others cannot cross cell membranes well.
Structural modification may also change their performance. Therefore, treatment benefits must be considered with practical barriers.
Certain products may require:
- Refrigeration
- Sterile preparation
- Injection training
Safety also differs between products. GLP-1 receptor agonists commonly cause gastrointestinal effects.
Ziconotide requires intrathecal administration. It also needs neurological monitoring.
Is there one general peptide safety profile? No. Each product needs its own assessment.
That review should consider:
- Its mechanism
- Its delivery method
- Its clinical evidence
Patient factors matter too. Kidney function may influence decisions. Liver function can also affect care. Other medicines require consideration. The patient’s treatment goals also matter. Healthcare professionals should avoid broad claims about peptide safety. Evidence for one product cannot automatically support another.
How could targeted peptide therapies change future care?
Peptides can help direct treatment toward selected receptors. They may carry:
- Medicines
- Imaging agents
- Radioactive materials
Peptide-drug conjugates use this approach. They combine a targeting peptide with another treatment. Researchers are studying these systems extensively in cancer care. The DCTPep cancer database contained 6,214 peptide-related entries in 2024 (Sun et al., 2024).
Those records covered:
- Approved therapies
- Clinical candidates
- Experimental sequences
Cell-penetrating peptides offer another approach. They may carry drugs into cells.
Some can transport genetic material. Others may carry nanoparticles. However, reliable tissue targeting remains difficult.
Peptides already support diagnosis too. Gallium-68 dotatate can identify certain neuroendocrine tumors. Lutetium-177 dotatate can then target the same receptor system. This pairing may improve patient selection. It may also support more focused treatment. This relationship combines diagnosis and therapy. It can show whether a tumor expresses the relevant receptor. Treatment may then target that same feature. However, these approaches need specialist imaging. They also require careful patient selection and coordinated follow-up.
How can regulatory knowledge protect patients?
Not every peptide product has the same regulatory status. That difference matters.
FDA-approved drugs undergo formal review. Regulators assess:
- Safety
- Effectiveness
- Manufacturing quality
Investigational products follow another path. They remain within regulated research programs.
Compounded preparations follow separate requirements. However, they do not receive standard FDA premarket approval.
Some products carry the label “research use only.” These products are not approved for patient treatment.
Can online availability prove safety? No. A product may look professional. Yet it may lack dependable clinical evidence.
Healthcare professionals should first identify the exact product. They should also confirm the manufacturer.
Next, they should review:
- The intended use
- The dose
- The regulatory status
Trial evidence deserves equal attention. Important details include:
- Study phase
- Participant numbers
- Follow-up periods
- Adverse events
- Study endpoints
These decisions involve professional responsibility. Therefore, legal ethics in healthcare remain relevant. They matter when clinicians assess uncertain or unapproved products.
The FDA has highlighted several peptide-specific concerns:
- Liver impairment
- Drug interactions
- QTc prolongation
- Immunogenicity
These concerns do not apply equally to every product. However, they show why each therapy needs specific evaluation.
Regulatory awareness helps clinicians avoid unsupported assumptions. It also supports clearer documentation. Informed consent may become safer too (U.S. Food and Drug Administration, 2023).
How can peptide knowledge improve patient conversations?
Patients now encounter peptide claims in many places. Sources include:
- Clinics
- Social media
- Product websites
- Online sellers
Some promotions use appealing terms:
- “Recovery”
- “Wellness”
- “Healthy aging”
These phrases may sound reassuring. However, they do not prove safety or effectiveness. Healthcare professionals need enough detail to explain the difference. Semaglutide has approved indications. It also has standardized formulations. Clinical trial data support its regulated uses.
A research chemical bought online may offer none of those protections.
Medication reviews should include:
- Injections
- Compounded products
- Online purchases
Clinicians should record:
- The product name
- The dose
- The source
- The patient’s treatment goal
In practice, careful medication planning for patients can reveal duplication. It can also identify unsafe combinations or unclear goals.
Teams should watch for duplicate therapies. Similar products may affect the same receptors.
Clear communication can reduce confusion. It may improve monitoring. It can also prevent avoidable harm. Professionals should explain what is known. They should also explain what remains uncertain. Product quality matters too. This approach respects patient interest. It does not validate unsupported claims. These conversations may involve several healthcare roles. Pharmacists can review formulations and interactions. Nurses may identify administration problems. Case managers may notice access or adherence barriers. Shared information helps the entire team respond consistently.
Why does staying current matter for responsible care?
Peptide medicines already influence many areas of healthcare. They support diabetes treatment. They also help with cancer imaging. Some products support pain management. Others address bone loss or rare diseases. Meanwhile, the field keeps expanding. New delivery systems are emerging. AI tools are supporting discovery. Targeted therapies are also becoming more advanced. Understanding advances in peptide science supports stronger clinical judgment. It helps professionals interpret new evidence. It also helps them avoid overstating findings. Current knowledge supports safer monitoring. It also leads to clearer patient conversations.
Author bio
Daniel Carter is a health and science writer. He covers clinical research, medical innovation, and patient education. His work makes complex healthcare topics clear for professional audiences. Outside of writing, Daniel enjoys hiking, reading history, and cooking for family and friends.
References
American Institute of Health Care Professionals. (2024, March 14). Case manager’s role in medication planning for patients. https://aihcp.net/2024/03/14/case-managers-role-in-medication-planning-for-patients/
American Institute of Health Care Professionals. (2025, January 10). The role of legal ethics in healthcare. https://aihcp.net/2025/01/10/the-role-of-legal-ethics-in-healthcare/
American Institute of Health Care Professionals. (2025, February 25). Lifelong learning in healthcare: Why continuing education matters. https://aihcp.net/2025/02/25/lifelong-learning-in-healthcare-why-continuing-education-matters/
American Institute of Health Care Professionals. (2025, July 1). Emerging trends in AI diagnostic tools shaping the future of accessible healthcare. https://aihcp.net/2025/07/01/emerging-trends-in-ai-diagnostic-tools-shaping-the-future-of-accessible-healthcare/
Sun, X., Liu, Y., Ma, T., Zhu, N., Lao, X., et al. (2024). DCTPep, the data of cancer therapy peptides. Scientific Data, 11, Article 541. https://doi.org/10.1038/s41597-024-03388-9
U.S. Food and Drug Administration. (2023, December). Clinical pharmacology considerations for peptide drug products: Draft guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-peptide-drug-products
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022). Therapeutic peptides: Current applications and future directions. Signal Transduction and Targeted Therapy, 7, Article 48. https://doi.org/10.1038/s41392-022-00904-4
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025). Advance in peptide-based drug development: Delivery platforms, therapeutics and vaccines. Signal Transduction and Targeted Therapy, 10, Article 74. https://doi.org/10.1038/s41392-024-02107-5
Please also review AIHCP’s Case Management Certification program and our CE courses as well, to see if they meet your academic and professional goals. These programs are online and independent study and open to qualified professionals seeking a four year certification